Herpes simplex virus encephalitis during treatment with etanercept.
Tumor necrosis factor alpha (TNF-α) inhibitors are widely used for the treatment of various inflammatory conditions. They are associated with an increased risk for infections. We report a case of herpes simplex virus type 1 (HSV-1) encephalitis in a patient receiving etanercept and review the literature on TNF-α and TNF-α inhibitors, and their importance in the pathophysiology of herpes simplex encephalitis.
From the Division of Infectious Diseases, Department of Medicine, George Washington University Medical Center.
Robbert H J
RH
Crusio
Stephanie V
SV
Singson
Faysal
F
Haroun
Hetal H
HH
Mehta
David M
DM
Parenti
D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology; D020803:Encephalitis, Herpes Simplex / Q000175:diagnosis* / Q000821:virology; D000068800:Etanercept; D018259:Herpesvirus 1, Human / Q000302:isolation & purification*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011859:Radiography; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept